Why the study?
Does the addition of trastuzumab to standard adjuvant chemotherapy increase the incidence of symptomatic heart failure?
Population
Patients from two large clinical trials receiving standard adjuvant chemotherapy. Medical records for a…
Comparison
Trastuzumab added to standard adjuvant… vs Standard adjuvant chemotherapy alone
Design
Cohort
Authors
Loading...
Supports cardiac monitoring with trastuzumab; leaves open reversibility and predictors in broader populations.
Does the addition of trastuzumab to standard adjuvant chemotherapy increase the incidence of symptomatic heart failure?
Adjuvant trastuzumab therapy is associated with a 2.0% incidence of symptomatic heart failure, which is higher than chemotherapy alone but largely reversible with appropriate treatment.
Russell et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: